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Octahedral platinum(IV) complexes such as trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] (1) are stable in the
dark, but potently cytotoxic to a range of cancer cells when activated by UVA or visible light, and active
in vivo. Photoactivation causes the reduction of the complex and leads to the formation of unusual Pt(II)
lesions on DNA. However, radicals are also generated in the excited state resulting from photoactivation
(J. S. Butler, J. A. Woods, N. J. Farrer, M. E. Newton and P. J. Sadler, J. Am. Chem. Soc., 2012, 134,
16508–16511). Here we show that once photoactivated, 1 also can interact with peptides, and therefore
proteins are potential targets of this candidate drug. High resolution FT-ICR MS studies show that
reactions of 1 activated by visible light with two neuropeptides Substance P, RPKPQQFFGLM-NH2 (SubP)
and [Lys]3-Bombesin, pEQKLGNQWAVGHLM-NH2 (K
3-Bom) give rise to unexpected products, in the
form of both oxidised and platinated peptides. Further MS/MS analysis using electron-capture
dissociation (ECD) dissociation pathways (enabling retention of the Pt complex during fragmentation),
and EPR experiments using the spin-trap DEPMPO, show that the products generated during the
photoactivation of 1 depend on the amino acid composition of the peptide. This work reveals the multi-
targeting nature of excited state platinum anticancer complexes. Not only can they target DNA, but also
peptides (and proteins) by sequence dependent platination and radical mechanisms.Introduction
Diazido platinum(IV) complexes such as trans,trans,trans-
[Pt(N3)2(OH)2(pyridine)2] (1) are promising agents for use in
Photo-Activated Chemotherapy (PACT),1,2 which oﬀers potential
temporal and spatial control over their activity,3–5 reducing side
eﬀects through unwanted attack on normal tissues.6,7
Complex 1 (scheme 1) and its analogues exhibit little activity
in the dark, yet possess potent antiproliferative activity in vitro
against a wide range of cancer cells upon irradiation with visible
light,8 and are also active in vivo towards oesophaegeal cancer
aer short time exposures to blue light.9 Furthermore, they do
not rely on the conversion of 3O2 to
1O2 to kill cancer cells, as
sensitisers used in photodynamic therapy (e.g. based on tetra-
pyrroles),10 which potentially can allow them to function eﬀec-
tively under the hypoxic conditions found in tumors.7,11,12
Complex 1 is more active than its cis isomer, and not cross
resistant with cisplatin.8 Its mechanism of action seems to
involve the platination of DNA by Pt(II) photoproducts, forming
inter-strand DNA cross-links, which are more diﬃcult to repairick, Gibbet Hill Road, Coventry CV4 7AL,
j.sadler@warwick.ac.uk; Fax: +44 (0)24
)24 76151008; +44 (0)24 765 23818
(ESI) available: Detailed MS data and
fragmentation, as Scheme S1, Tables
/c7sc05135b
hemistry 2018than DNA-adducts formed by cis-analogues.11 However, radicals
are also generated during irradiation of the complex with visible
light.1,6,13,14 Initially it was believed that the mechanism of
photodecomposition of 1 simply involved excitation of the
ligand(azide)-to-metal (PtIV) charge-transfer band, with one-
electron transfer from each azide ligand giving rise to PtII and
two azidyl radicals which can combine to form three molecules
of N2.1 However, the detailed photodecomposition pathways are
complex, can lead to the production of azidyl radicals, singletScheme 1 Trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 1), the
photo-activatable prodrug used in this study, along with illustrative
photo-decomposition pathways leading to PtII products which can
form bonds/inter-strand cross-links on DNA.1
Chem. Sci., 2018, 9, 2733–2739 | 2733
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View Article Onlineoxygen (even in absence of gaseous O2), nitrenes, and hydroxyl
radicals,1,6,13,14 and depend strongly on the biomolecules
present. For example, loss of N2 from a bound azide can lead to
nitrene intermediates whichmight attack thioethers such as the
side-chain of methionine.15 Additionally, the production of
azidyl radicals is quenched in the presence of tryptophan (but
not other amino acids such as glycine or tyrosine).14 This
suggests that 1might interact with peptides and proteins inside
cells, following diﬀerent photodecomposition pathways
depending on their sequences. However, the interaction of
photoactivated 1 with peptides has yet to be studied.
Tandem mass spectrometry (MS/MS) analysis has been
successful in studying an array of peptides and proteins while
retaining vital post-translational modications (PTM's).16–18
This technique has been used to investigate the interactions of
biomolecules with platinum drugs such as cisplatin,19–21 trans-
platin,22 oxaliplatin,23 or diiodido–platinum complexes,24 but
also ruthenium,25–28 and organometallic iridium and osmium
complexes.29,30 Electron-based dissociations are particularly
useful when studying metallodrug interactions where the top-
down approach has allowed the characterisation of entire
protein sequences and the unambiguous determination of
multiple binding sites for metallodrugs on various
proteins,21,31–33 without further chemical modications such as
digestion which can disrupt/dissociate modications. Electron
capture dissociation (ECD) MS/MS is particularly eﬀective for
PTM analysis due to its non-ergodic character34 and its ability to
fragment species without loss of fragile PTM's.35
Herein, we use ultra-high resolution Fourier Transform Ion
Cyclotron Resonance Mass Spectrometry (UHR-FT-ICR MS)
to study the interaction of trans,trans,trans-[Pt(N3)2
(OH)2(pyridine)2] (1) with two model peptides (neuropeptides);
Substance P, RPKPQQFFGLM-NH2 (SubP), and [Lys]
3-Bomb-
esin, pyrQKLGNQWAVGHLM-NH2 (K
3-Bom). Both of which
have amidated C-termini. Our experiments show for the rst
time that photoactivation of 1 leads to both amino-acid-specic
platination and oxygenation of peptides.Fig. 1 nESI FT-ICR mass spectra of (a) ca. 1 mM aqueous complex
1+SubP, and (b) complex 1+K3-Bom reaction mixtures (0.5 : 1
drug : peptide ratio) after 1 and 2 h of irradiation (respectively) with
blue visible light (463 nm). Inset; various isotopic patterns for the
observed (obs.) and calculated (calc.) species assigned from the mass
spectra – showing the inﬂuence of platinum on observed isotopic
distributions. Green ﬁlled circles indicate unmodiﬁed peptide species,
red indicates oxidised species (both peptide and platinated peptides),
other colours indicate platinated peptide species with diﬀerent Pt(II)-
based modiﬁcations.Results and discussion
K3-Bom and SubP are naturally occurring peptides with a role in
some types of cancer; K3-Bom is a known tumour marker,36 and
SubP has elevated levels in several types of cancer cells.37 Initial
experiments showed that the use of bright red light during
sample preparation and analysis had no eﬀect on 1, while low
levels of white light induced the photoactivation of the complex.
Therefore, all samples were prepared and analysed in darkness
or with very low levels of red light, to avoid activation of 1 prior
to irradiation with blue light.
Photoactivation of 1 in presence of SubP or K3-Bom was rst
followed using UV-vis spectroscopy (Fig. S1†). Complex 1
exhibits an intense azide-to-Pt(IV) charge-transfer band (lmax ¼
295 nm) which can be used to monitor the photodecomposition
of the complex.1 SubP had little apparent eﬀect on the rate of
decomposition of 1. However, K3-Bom slowed this process, and
induced the formation of a new peak at ca. 250 nm.2734 | Chem. Sci., 2018, 9, 2733–2739Using nESI-FT-ICR-MS, we analysed reaction mixtures of
1+SubP and 1+K3-Bom (0.5–1 drug : peptide) irradiated with
blue light (463 nm; 30–120 min) to activate 1. Peaks for a total of
8 and 12 products were assigned for the reactions of 1+SubP and
1+K3-Bom, respectively (Fig. 1, Table S2†). Most can be assigned
to diﬀerent platinated adducts of the peptides. For the reaction
between 1+SubP, only mono-platinated adducts were observed,
containing the modications {Pt(py)(OH)(N3)}, {Pt(py)2(N3)},
{Pt(N3),}, and {Pt(py)2} with reasonable intensity, and
{Pt(py)2(OH)} at low intensity. However, analysis of the reaction
1+K3-Bom showed both mono- and di-platinated adducts, con-
taining {Pt(py)2}, {Pt(py)2(N3)}, {Pt(py)2(OH)}, and both {Pt(py)2}
and {Pt(py)2(N3)} modications simultaneously.
Interestingly, both unmodied and platinated adducts of the
peptides were found to be oxidised when irradiated in presence
of 1. SubP species had the addition of one oxygen (by exact
mass), while up to three oxygen atoms were found on K3-Bom
species. Similar species were not observed upon irradiation of
the peptides in absence of 1, or when 1 + peptide mixtures
where not irradiated with blue light.
Photoactivated platination of [Lys]3-Bombesin
Platinum-containing K3-Bom adducts were readily identied in
MS and MS/MS spectra by platinum's characteristic isotopic
pattern (Fig. 1, inset). Clear peaks for various platinated species
can be observed simultaneously, showing release of 1-2
hydroxido ligands and 1-2 azido ligands. Retention of theThis journal is © The Royal Society of Chemistry 2018
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
Fe
br
ua
ry
 2
01
8.
 D
ow
nl
oa
de
d 
on
 2
/1
9/
20
19
 4
:3
1:
21
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinepyridine ligands during the photoactivation of 1 correlates well
with previous 1H-NMR experiments on model reactions with
guanine derivatives,6,11 as do products in which one azido ligand
remains bound in the case of the {Pt(py)2(N3)}
+ modication.6
ECD MS/MS analysis of the platinated K3-Bom species is
summarised in Fig. 2. Full assignment lists and ECD MS/MS
spectra are in Tables S2–S4 and Fig. S2.†K3-Bom contains
methionine, histidine and lysine residues, all potential S or N
donor ligands. Pt(II) complexes are known to bind preferentially
at the S of Met, followed by His N.20,32,38–40 Pt–S bonds are usually
strong, and survive harsh pH digestions and high energy gas
phase dissociations in tandem MS experiments.20 However,
{Pt(py)2(N3)}
+ and {Pt(py)2(OH)}
+ modications from mono-
platinated K3-Bom adducts were unambiguously bound at the
His12 residue, despite the C-terminal Met.14 MS/MS analysis of
[K3-Bom+Pt(py)2]
2+ species yielded no sequence-informative
fragments, only ligand and/or amino acid side chain loss
peaks. Such behaviour has been attributed to extended cyclic
structures which can disrupt usual MS/MS fragmentation.41
However, the presence of metal centres presents unique chal-
lenges to MS and MS/MS peptide/protein analysis.41–44
The charged Pt centre altered the ECD MS/MS fragmentation
pattern by providing a xed charge at the point of interaction
(e.g. His11 of K3-Bom), but also enhanced side chain losses of
amino acid groups present. Electron capture at the PtII centre/
electron transfer of previously captured electrons on the
peptide also caused additional ligand loss from the bound
complex and additional fragmentations from amino acid resi-
dues, including unique side chain losses from methionine resi-
dues (Scheme S1†). CADMS/MS of platinum complex-containing
species caused gas-phase dissociation of the platinum-bound
ligands, even at low energies (<5–7 V), creating a reactive PtII
centre, which quickly cyclised with available peptide groups and
produced uninformative fragmentation spectra.
Still, ECD MS/MS of [K3-Bom+Pt(py)2+H]
3+ species produced
abundant backbone fragmentation (Fig. S2c†). This showed
simultaneous binding at His12 and Met14 residues of {Pt(py)2}
photoproducts, producing a small cyclic region in the modied
peptide species.Fig. 2 Platinated K3-Bom peptide species observed and fragmented
by ECD MS/MS; coloured squares indicate a modiﬁcation observed on
the particular fragment. Thesemodiﬁcations can be readily assigned to
single amino acid residues. Fully annotated spectra are shown in
Fig. S2.†
This journal is © The Royal Society of Chemistry 2018Photoactivated platination of substance P
Unlike K3-Bom, SubP contains no histidine residues, and pho-
toactivation of 1+SubP mixture led to loss of a pyridine ligand,
producing ({Pt(py)(OH)(N3)} as a major peptide modication;
Fig. 1a and 3). This suggests that all the types of ligands found
in 1 can be released during photoirradiation, and highlights the
importance of peptide sequence in determining the pathways
followed during photodecomposition.
ECD MS/MS shows that [SubP+{Pt(py)(OH)(N3)}+2H]
2+,
[SubP+{Pt(py)2(N3)}+H]
2+, [SubP+{Pt(N3)+H]
2+, and
[SubP+{Pt(py)2+H}]
3+ species are platinated within the four N-
terminal amino acids of the peptide (Fig. 2, Tables S5–7,
Fig. S3†). [SubP+{Pt(py)2(OH)}+H]
2+ species were observed only
at very low intensity at all irradiation times, and reliable MS/MS
fragmentation could not be obtained. ECD induced fragmen-
tation of the N-terminal region of SubP (RPKP) is restricted by
proline residues,45 and the overall structure is held together via
the “proline eﬀect”.46 This hampered determination of the
platination sites of SubP. However, the fragmentation allowed
the binding site for 1 to be located between Lys3 and Pro.4
Interestingly, spectra from 1+K3-Bommixtures aer diﬀerent
irradiation times (30, 60, 90 or 120 min) always contained the
same photoproducts, increasing their overall, but not their
relative intensity at longer irradiation times. However, irradia-
tion of 1+SubPmixtures for diﬀerent times showed preferential
formation of diﬀerent products at diﬀerent times.
[SubP+Pt(py)(OH)(N3)+2H]
2+ was the major product at short
irradiation times, while longer irradiations of 1+SubP mixtures
led to further ligand release, with [SubP+Pt(N3)+H]
2+ species
increasing over time. This suggests that photoreactions of 1 can
continue aer the formation of Pt(II) species.Methionine and tryptophan oxidation
In addition to peptide platination; an array of oxidised products
was also observed following photoactivation of 1. Oxidised
peptide species (i.e. [SubP+O+2H]2+, [K3-Bom+O+2H]2+, [K3-
Bom+2O+2H]2+, and [K3-Bom+3O+2H]2+) were further studiedFig. 3 Platinated SubP peptide species observed and fragmented by
ECD MS/MS; coloured squares indicate a modiﬁcation on the partic-
ular fragment. Fully annotated spectra are shown in Fig. S3.†
Chem. Sci., 2018, 9, 2733–2739 | 2735
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View Article Onlineusing FT-ICR-MS and ECD MS/MS (Fig. 4 and S5, Tables S8–
S11†). Fragmentation maps revealed that oxidation of the
peptides occurs at Met11 for SubP and Met14 and Trp8 for
K3-Bom. Methionine residues in both peptides can be oxidised
to the sulfoxide,47 and further to sulfone species.48 However,
MS/MS shows that photoactivation of 1 in presence of the
peptides K3-Bom and SubP led only to the formation of sulf-
oxide species.
Both mono- and di-oxidised K3-Bom species showed a two-
product fragment distribution, relating to oxidation at Met14
or Trp8 for mono-oxidised species, and to single oxidation of
both Met14 and Trp8 residues, or double oxidation of Trp8 for di-
oxidised species (Fig. 4, Tables S9–11, Fig. S5b–c†).
[K3-Bom+3O+2H]2+ species showed both oxidation at Met14 and
double oxidation of Trp8 residues. Tryptophan oxidation is
known to give rise to a variety of side-chain modications,
which are dependent of the nature of the oxidising agent.49,50
Hydroxy-tryptophan (HTRP) and N-formyl kynurenine(NFK) areScheme 2 Possible oxidation products arising from 1O2 (KYN and
3OH-KYN) and radical (HTRP and NFK) oxidation of a tryptophan side-
chain50,51 along with corresponding calculated mass changes for the
modiﬁcations. Singlet oxygen induced processes are shown in red,
while those induced by hydroxyl radical processes are shown in blue.
Fig. 4 Oxidised peptide species observed and fragmented by ECD
MS/MS. Oxidative modiﬁcations (indicated by red squares) can be
readily located on single amino acid residues (highlighted). Fully
annotated tandem mass spectra can be found in the ESI (Fig. S5†).
2736 | Chem. Sci., 2018, 9, 2733–2739formed when the 5-membered indole ring of tryptophan is
attacked by hydroxyl radicals, while kynurenine (KYN) and 3-
hydroxy-kynurenine (3OH-KYN) arise from singlet oxygen-
induced oxidation (Scheme 2). These reaction products have
diﬀerent mass changes compared to the original amino acid,
and can be used to provide insights into the mechanism of the
oxidation itself.50
UHR-FT-ICR MS spectra of 1+K3-Bom mixtures (Fig. 1b) and
the corresponding MS/MS spectra (Fig. S2a–d†) show clearlyFig. 5 EPR spectra showing the radicals trapped by DEPMPO during
the photoactivation (with blue visible light) of (a) 1 (b) 1+SubP and (c)
1+K3-Bom. Inset shows simulations of corresponding spectra and the
structures of the spin-trapped azidyl radicals (a + b) and oxidised
DEPMPO arising from attack by the high concentration of OH radicals
produced via photoactivation of 1 with K3-Bom (c).52
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinethat tryptophan oxidation leads to the formation of HTRP and
NFK for the mono and di-oxidised species, respectively
(+15.994915 Da and +31.989829 Da mass shis). This suggests
that hydroxyl radicals are generated when 1 is photoactivated in
the presence of K3-Bom, and are responsible for the oxidation of
methionine and tryptophan residues. Electron transfer from an
axial hydroxido ligand and an azido ligand to PtIV can result in
retention of one N3 ligand in the Pt
II photo-product (Fig. 1).
Detection of radicals
EPR was used to trap radicals generated during the photo-
activation of 1, 1+SubP, and 1+K3-Bom with DEPMPO as the
spin trap (Fig. 5, Table S12, Fig. S6†). Azidyl radicals were
trapped during the photoactivation of complex 1 alone, and also
from 1+SubPmixtures. However, the EPR spectra obtained from
irradiation of 1+K3-Bom mixtures were dramatically diﬀerent.
Oxidised adducts of the DEPMPO trap were observed
(DEPMPOX, Fig 5c). Such species can be formed by oxidation of
DEPMPO-OH adducts,52 and arising from the attack by hydroxyl
radicals. These studies therefore conrm that the photoreaction
pathways for complex 1 can therefore not only involve electron
transfer from azide ligand to PtIV but also from an hydroxido
ligand to form N3c and HOc radicals.
Eﬀect of free tryptophan on peptide oxidation
Reaction mixtures containing SubP+1+L-Trp and K3-Bom+1+L-
Trp (mol ratio 2 : 1 : 0.13 (peptide : drug : Trp); 31 mMTrp) were
irradiated with blue light (463 nm) for 60 and 120 min,
respectively, min and monitored by nESI-FT-ICR-MS (Table S13,
Fig. S7†). Addition of Trp had little eﬀect on the type of species
produced and peptide platination observed in the photoreac-
tion of SubP+1. However, Trp reduced the level of peptide
oxidation by 29% and 95% for non-platinated and platinated-
oxidised species, respectively. Trp aﬀected more dramatically
the photoreaction of K3-Bom+1 mixtures. Every oxidised and
platinated species was reduced in intensity (except [K3-
Bom+O]2+ and [K3-Bom+3O]2+) by 32–98%. This suggests that
the Trp residue in K3-Bom itself could play a role in determining
the extent of platination of the peptide.
Conclusions
These studies show for the rst time that photoactivation of the
diazido PtIV anticancer prodrug 1 can readily lead to a dual
attack on peptide amino acids, either oxidation, or platination,
or both. Additionally, the amino acid composition can have
a dramatic eﬀect on determining the course of the reactions.
Both SubP and K3-Bom were oxidised, platinated, and oxidised
and platinated on photoactivation of complex 1, but the nature
of the bound photoproducts of 1 and the amino acid residues
modied depend on the amino acid composition of the peptide.
His12 of K3-Bom was preferentially platinated, and both pyridine
ligands were retained in all the photoproducts observed,
whereas for SubP, a diﬀerent range of products was observed,
and complex 1 released one or two pyridine ligands with
apparent binding to Lys,3 and Arg1 residues. Photoactivation ledThis journal is © The Royal Society of Chemistry 2018to the oxidation of specic sites in both peptides. For SubP
oxidation occurred only at Met,11 whereas for K3-Bom, up to
three stages of oxidation were observed: oxidation at Met14 and
a single or double oxidation of the Trp8 residue. This is the rst
observation of Met and Trp oxidation by this class of photo-
activatable platinum anticancer complexes. Trp modication
yielded hydroxytryptophan (HTRP) and N-formylkynurenine
(NFK) species (Scheme 2), indicating that hydroxyl radicals are
responsible for the oxidative attack. Interestingly, oxidation of
Trp to NFK is also a critical step in the biological production of
NAD+. The dependence of radical generation on the nature of
the peptide was further conrmed by EPR spin-trapping.
The role of tryptophan as a redox-active amino acid,53 and
the formation of HTRP and NFK species suggest that radical-
based processes might play an important role in the mecha-
nism of action of this class of PtIV photoactivated complexes.
Such production of oxidative stress may provide some selectivity
for attack on cancer cells versus normal cells, since cancer cells
have malfunctioning mitochondria and are particularly
susceptible to redox stress.54–56
Experimental
Substance P, [Lys]3-bombesin, and formic acid were purchased
from Sigma Aldrich Company Ltd., Dorset, UK. Low concen-
tration Agilent tuning mix was purchased from Agilent Tech-
nologies (Santa Clara, CA). Complex 1 was synthesised and
characterised as described elsewhere.6 EPR tubes were
purchased from Wilmad Labglass. The spin trap 5-(diethox-
yphosphoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO) was ob-
tained from Enzo Life Sciences in high purity. Ultra-pure water
was obtained from a Milli-Q UV III system (Milli-Q, Hertford-
shire, UK).
Reactions of peptides with 1
Aliquots of aqueous solutions of Substance P (1 mM) and [Lys]3-
Bombesin (1 mM) were mixed with an aqueous solution of 1
(250 mM) to give solutions of 0.5 : 1 drug : peptidemol ratio. The
samples were then irradiated under 463 nm (blue visible) light
at 298 K for various times, before being diluted to MS concen-
trations (ca. 1 mM) and either analysed immediately or frozen at
80 C prior to MS analysis. Freshly prepared samples were
compared to those frozen for one to several weeks and showed
no observable variation in the mass spectra obtained. Reactions
involving tryptophan were carried out using similar procedures
as above together with the addition of aqueous tryptophan
solution (1 mM) to peptide + 1 solutions to achieve amol ratio of
0.5 : 1 : 0.125 (drug : peptide : tryptophan), i.e. concentration of
tryptophan was 1/8th of drug concentration, as used previously
by Butler et al.14
FT-ICR mass spectrometry
Nano-electrospray (nESI) mass spectrometry was performed on
a Bruker SolariX Fourier Transform Ion Cyclotron Resonance
Mass spectrometer (FT-ICR MS) tted with a 12 tesla actively
shielded magnet (Bruker Daltonics, Bremen, Germany).Chem. Sci., 2018, 9, 2733–2739 | 2737
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View Article OnlineAqueous peptide samples (1 mM) were spiked with 0.3% formic
acid (v/v) to aid ionisation during nESI. Solutions containing 1
(including reaction mixtures) were analysed via nESI in Milli-Q
water with no added acid.
For ECDMS/MS analysis; the species of interest were isolated
in the rst quadrupole, externally accumulated in the collision
cell for 0.1–7 s and then transferred to the innity cell for
Electron Capture Dissociation (ECD) fragmentation and detec-
tion. Ions in the innity cell were irradiated with 1.3–1.6 eV
electrons from a 1.5 A hollow cathode dispenser for 50–600 ms
prior to detection.
MS/MS spectra were internally calibrated using the minimal
number of unmodied (peptide spectra) or modied (Pt adduct
spectra) c/z ions and the charge reduced species [M + nH]n1+c
where possible (species used for calibration are marked). A
dual-spray nESI experiment was also conducted using the [K3-
Bom+2H]2+ ion and ions from Agilent Tune mix, utilising an in-
cell isolation (Multi-CHEF)57 and identical ECD parameters to
validate the internal calibration of the MS/MS spectra. Similar
standard deviations were found for the ECD fragmentation
spectra when calibrated with either fragment ions or with tune-
mix peaks (see ESI Fig. S8 and Table S14†). This dual-spray
Multi-CHEF ECD approach was also used for some 1 +
peptide reaction product ECD spectra to improve the internal
calibration (spectra and calibration peaks marked accordingly).
Electron paramagnetic resonance (EPR)
EPR spectra were recorded at ambient temperature on a Bruker
EMX (X-band) spectrometer tted with a cylindrical TM110
mode cavity (Bruker 4103TM). Samples were contained in
a quartz capillary tube (I.D. 1.0 mm; O.D. 1.2 mm; Wilmad
Labglass) sealed with T-Blu Tac®, placed inside larger quartz
tubes (O.D. 2.0 mm) to achieve easy and accurate positioning of
the sample inside the resonator. Typical key EPR spectrometer
settings were modulation amplitude 2.0 G, microwave power
0.63 mW, 1.0  105 receiver gain, conversion time 81.92 ms,
time constant 81.92 ms, sweep width 200 G, and a repeated
number of 10 X-scans with a resolution in Y of 5 or 9. Spin-
trapping experiments were performed on aqueous solutions of
the complex with excess of spin trap (1 mM 1, 6 mM DEPMPO)
in the presence or absence of peptides (1 mM). A visible blue
light emitting diode (LED, l ¼ 463 nm, 64 mW cm2) was used
as the source of irradiation and placed at a distance of 8.5 cm
from the tube in the EPR cavity. Irradiations lasted up to 2 h,
each slice corresponding to 14min of irradiation (10 scans). The
TM110 EPR cavity used is equipped with a grid on one side
allowing optical access (ca., 50%) transmission. The refractive
index of quartz is approximately 1.55; hence at normal inci-
dence approximately 5% of the incident light is reected at an
air quartz interface. EPR spectra were analysed and simulated
using the EASYSPIN soware.58
UV-vis spectroscopy
Aqueous solutions of 1 (60 mM), SubP (120 mM), K3-Bom
(120 mM), 1 (60 mM) + SubP (120 mM), and 1 (60 mM) + K3-Bom
(120 mM) were prepared and irradiated as above, then studied2738 | Chem. Sci., 2018, 9, 2733–2739using a Cary 300 scan UV-visible spectrophotometer (Agilent,
California, US). Solutions were analysed in quartz cuvettes
(0.5 mL, 1 cm path length), with scanning in the region of
200–800 nm at a rate of 10 nm s1 (600 nm min1), average
time ¼ 0.1 s, data interval 1 nm.
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